VanEck Pharmaceutical ETF(PPH · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $81.74 – $112.58
- YTD
- +0.91%
- IV Rank (30D)
- 82.04
- Straddle Price
- $6.55
- P/C Vol Ratio
- 0.21
VanEck Pharmaceutical ETF (PPH) ETF
- Exchange
- XNAS
- Inception
- 2011-12-20
- Has Options
- Yes
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-04-01 | 2026-04-07 | $0.8441 | CD |
| 2025-12-29 | 2025-12-31 | $0.3106 | CD |
| 2025-10-01 | 2025-10-06 | $0.3931 | CD |
| 2025-07-01 | 2025-07-07 | $0.6069 | CD |
| 2025-04-01 | 2025-04-04 | $0.5245 | CD |
| 2024-12-27 | 2024-12-30 | $0.4110 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| LLY | Eli Lilly & Co | 22.65% | Equity (US) | — |
| NVS | Novartis Ag | 10.35% | Equity (US) | — |
| MRK | Merck & Co Inc | 9.58% | Equity (US) | — |
| NVO | Novo Nordisk A/S | 5.54% | Equity (US) | — |
| PFE | Pfizer Inc | 4.77% | Equity (US) | — |
| SNY | Sanofi Sa/France | 4.35% | Equity (US) | — |
| BMY | Bristol-Myers Squibb Co | 4.30% | Equity (US) | — |
| ABBV | Abbvie Inc | 4.24% | Equity (US) | — |
| GSK | Gsk Plc | 4.21% | Equity (US) | — |
| AZN | Astrazeneca Plc | 4.08% | Equity (US) | — |
| JNJ | Johnson & Johnson | 4.07% | Equity (US) | — |
| MCK | Mckesson Corp | 3.74% | Equity (US) | — |
| COR | Cencora Inc | 3.22% | Equity (US) | — |
| TEVA | Teva Pharmaceutical Industries Ltd | 3.16% | Equity (US) | — |
| HLN | Haleon Plc | 2.89% | Equity (US) | — |
| TAK | Takeda Pharmaceutical Co Ltd | 2.61% | Equity (US) | — |
| ZTS | Zoetis Inc | 2.30% | Equity (US) | — |
| VTRS | Viatris Inc | 1.04% | Equity (US) | — |
| JAZZ | Jazz Pharmaceuticals Plc | 0.99% | Equity (US) | — |
| AXSM | Axsome Therapeutics Inc | 0.70% | Equity (US) | — |
| CORT | Corcept Therapeutics Inc | 0.39% | Equity (US) | — |
| ELAN | Elanco Animal Health Inc | 0.34% | Equity (US) | — |
| OGN | Organon & Co | 0.22% | Equity (US) | — |
| — | Other/Cash | 0.18% | Cash/Money Market | — |
| BHC | Bausch Health Cos Inc | 0.10% | Equity (US) | — |
| PRGO | Perrigo Co Plc | 0.07% | Equity (US) | — |
| — | Cash | -0.10% | Cash/Money Market | — |
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Eli Lilly & Co | Eli Lilly & Co | 20.79% | $265.5M |
| 2 | Novartis AG | Novartis AG | 10.04% | $128.3M |
| 3 | Merck & Co Inc | Merck & Co Inc | 8.90% | $113.7M |
| 4 | Novo Nordisk A/S | Novo Nordisk A/S | 6.45% | $82.4M |
| 5 | Pfizer Inc | Pfizer Inc | 4.64% | $59.3M |
| 6 | Bristol-Myers Squibb Co | Bristol-Myers Squibb Co | 4.55% | $58.2M |
| 7 | AbbVie Inc | AbbVie Inc | 4.39% | $56.1M |
| 8 | GSK PLC | GSK PLC | 4.38% | $56.0M |
| 9 | McKesson Corp | McKesson Corp | 4.36% | $55.7M |
| 10 | AstraZeneca PLC | AstraZeneca PLC | 4.34% | $55.5M |
| 11 | Sanofi SA | Sanofi SA | 4.34% | $55.5M |
| 12 | Johnson & Johnson | Johnson & Johnson | 4.33% | $55.4M |
| 13 | Cencora Inc | Cencora Inc | 3.96% | $50.6M |
| 14 | Zoetis Inc | Zoetis Inc | 3.48% | $44.5M |
| 15 | Haleon PLC | Haleon PLC | 3.00% | $38.3M |
| 16 | Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries Ltd | 2.60% | $33.3M |
| 17 | Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd | 2.58% | $33.0M |
| 18 | Viatris Inc | Viatris Inc | 0.75% | $9.5M |
| 19 | Jazz Pharmaceuticals PLC | Jazz Pharmaceuticals PLC | 0.63% | $8.1M |
| 20 | Axsome Therapeutics Inc | Axsome Therapeutics Inc | 0.49% | $6.3M |
| 21 | Elanco Animal Health Inc | Elanco Animal Health Inc | 0.43% | $5.5M |
| 22 | Corcept Therapeutics Inc | Corcept Therapeutics Inc | 0.17% | $2.2M |
| 23 | Bausch Health Cos Inc | Bausch Health Cos Inc | 0.11% | $1.4M |
| 24 | Organon & Co | Organon & Co | 0.11% | $1.4M |
| 25 | Perrigo Co PLC | Perrigo Co PLC | 0.09% | $1.1M |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 5.61% | $71.7M | 1 |
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.64% | 23 |
| Feb | +0.28% | 23 |
| Mar | +0.06% | 23 |
| Apr | +1.45% | 23 |
| May | +0.58% | 23 |
| Jun | +0.45% | 23 |
| Jul | +0.94% | 22 |
| Aug | -0.16% | 22 |
| Sep | -0.84% | 22 |
| Oct | -1.05% | 22 |
| Nov | +1.86% | 22 |
| Dec | +1.05% | 22 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
- IV Rank (30D)
- 82.04
- IV Rank (7D)
- 60.17
- Avg IV
- 39.6%
- Straddle (30D)
- $6.55
- Straddle (7D)
- $3.50
- P/C Volume
- 0.21
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.45
- Correlation (SPY)
- 31.3%
- R²
- 0.10
- Ann. Volatility
- 17.4%
- SPY Volatility
- 12.1%
Low volatility - stock moves less than market
Click any bar to view the full quote for that stock.
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|